DAVID LONARD to Antineoplastic Agents
This is a "connection" page, showing publications DAVID LONARD has written about Antineoplastic Agents.
Connection Strength
1.211
-
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. Sci Rep. 2019 10 22; 9(1):15099.
Score: 0.319
-
Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers. Biochem Pharmacol. 2017 09 15; 140:1-7.
Score: 0.267
-
Molecular Pathways: Targeting Steroid Receptor Coactivators in Cancer. Clin Cancer Res. 2016 Nov 15; 22(22):5403-5407.
Score: 0.257
-
Lead Compound Development of SRC-3 Inhibitors with Improved Pharmacokinetic Properties and Anticancer Efficacy. J Med Chem. 2024 04 11; 67(7):5333-5350.
Score: 0.108
-
SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Cancer Lett. 2019 02 01; 442:310-319.
Score: 0.075
-
The Role of Steroid Receptor Coactivators in Hormone Dependent Cancers and Their Potential as Therapeutic Targets. Horm Cancer. 2016 08; 7(4):229-35.
Score: 0.063
-
Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol. 2011 Dec; 25(12):2041-53.
Score: 0.046
-
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS One. 2024; 19(4):e0289902.
Score: 0.027
-
Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun. 2021 02 15; 12(1):1022.
Score: 0.022
-
HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75.
Score: 0.015
-
SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. Genes Dev. 2013 Feb 01; 27(3):274-87.
Score: 0.012